Repatha manufacturer
Searched over 200M research papers for "repatha manufacturer"
Summary
10 papers analyzed
These studies suggest that Repatha, manufactured as Evolocumab, is an injectable PCSK9 inhibitor used to lower LDL-cholesterol in patients with various forms of hypercholesterolemia and is approved in multiple regions including the EU and USA.
Not a yes or no question
To use the Consensus Meter, try asking a simple yes or no question
Research summarized with Copilot
Beta20 papers analyzed
Repatha Manufacturer: Amgen's Role in Hypercholesterolemia Treatment
Introduction to Repatha (Evolocumab)
Repatha, known generically as evolocumab, is a groundbreaking medication developed by Amgen for the treatment of hypercholesterolemia. This fully human monoclonal antibody targets proprotein convertase subtilisin/kexin type 9 (PCSK9), a protein that regulates low-density lipoprotein (LDL) receptors, thereby playing a crucial role in cholesterol metabolism .
Mechanism of Action: PCSK9 Inhibition
Evolocumab works by binding to PCSK9, preventing it from degrading LDL receptors on liver cells. This action enhances the liver's ability to remove LDL cholesterol (LDL-C) from the bloodstream, significantly lowering LDL-C levels . This mechanism is particularly beneficial for patients who have not achieved their LDL-C targets with statins alone or who are statin-intolerant .
Clinical Efficacy and Approvals
FDA and Global Approvals
Repatha has received approval from the FDA and other regulatory bodies worldwide for use in adults with heterozygous familial hypercholesterolemia (HeFH), clinical atherosclerotic cardiovascular disease, and homozygous familial hypercholesterolemia (HoFH) . The drug is administered subcutaneously, either every two weeks or once a month, depending on the dosage .
Clinical Trials and Efficacy
Clinical trials have demonstrated that evolocumab can reduce LDL-C levels by up to 60% when used in conjunction with statins . The FOURIER trial further established that evolocumab significantly reduces the incidence of major cardiovascular events, making it a valuable option for secondary prevention in patients with atherosclerotic cardiovascular disease.
Safety and Tolerability
Evolocumab has been well-tolerated in clinical trials, with a safety profile comparable to placebo and other lipid-lowering therapies . The drug has shown no significant adverse effects on cognitive function, which is a critical consideration for long-term use.
Economic Considerations
Despite its clinical benefits, the high cost of Repatha has been a point of contention. Studies suggest that the price of evolocumab needs to be significantly reduced to be considered cost-effective, especially when used as an adjunct to statins. This economic challenge remains a barrier to its widespread adoption.
Conclusion
Amgen's Repatha (evolocumab) represents a significant advancement in the treatment of hypercholesterolemia, particularly for patients who cannot achieve their LDL-C targets with traditional therapies. Its ability to significantly lower LDL-C levels and reduce cardiovascular events makes it a valuable therapeutic option. However, its high cost poses a challenge to its broader use, necessitating discussions on pricing to enhance its accessibility and cost-effectiveness.
Sources and full results
Most relevant research papers on this topic
